Abstract
In silico pharmacology is a promising field in the current state-of drug discovery. This area exploits “proteinprotein Interaction (PPI) network analysis for drug discovery using the drug “target class”. To document the current status, we have discussed in this article how this an integrated system of PPI networks contribute to understand the disease pathways, present state-of-the-art drug target discovery and drug discovery process. This review article enhances our knowledge on conventional drug discovery and current drug discovery using in silico techniques, best “target class”, universal architecture of PPI networks, the present scenario of disease pathways and protein-protein interaction networks as well as the method to comprehend the PPI networks. Taken all together, ultimately a snapshot has been discussed to be familiar with how PPI network architecture can used to validate a drug target. At the conclusion, we have illustrated the future directions of PPI in target discovery and drug-design.
Keywords: PPI network, drug discovery.
Current Protein & Peptide Science
Title:Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Volume: 15 Issue: 6
Author(s): Chiranjib Chakraborty, George Priya Doss. C, Luonan Chen and Hailong Zhu
Affiliation:
Keywords: PPI network, drug discovery.
Abstract: In silico pharmacology is a promising field in the current state-of drug discovery. This area exploits “proteinprotein Interaction (PPI) network analysis for drug discovery using the drug “target class”. To document the current status, we have discussed in this article how this an integrated system of PPI networks contribute to understand the disease pathways, present state-of-the-art drug target discovery and drug discovery process. This review article enhances our knowledge on conventional drug discovery and current drug discovery using in silico techniques, best “target class”, universal architecture of PPI networks, the present scenario of disease pathways and protein-protein interaction networks as well as the method to comprehend the PPI networks. Taken all together, ultimately a snapshot has been discussed to be familiar with how PPI network architecture can used to validate a drug target. At the conclusion, we have illustrated the future directions of PPI in target discovery and drug-design.
Export Options
About this article
Cite this article as:
Chakraborty Chiranjib, C Priya Doss. George, Chen Luonan and Zhu Hailong, Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`, Current Protein & Peptide Science 2014; 15 (6) . https://dx.doi.org/10.2174/1389203715666140724090153
DOI https://dx.doi.org/10.2174/1389203715666140724090153 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Genetically Engineered Mouse Models for Drug Discovery: New Chemical Genetic Approaches
Current Drug Discovery Technologies Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry The Development of a Rapid, Simple and Sensitive LC-MS/MS Method, to Guide Clinical Dosing, for the Analysis of 5-Fluorouracil in Human Plasma
Current Pharmaceutical Analysis Robotic Assisted Surgery in Gynecology: Current Insights and Future Perspectives
Recent Patents on Biotechnology Molecular Insight into the Inhibitory Mechanism of Galangin Towards Human Cytochrome P450 1A2. A Modeling Study
Letters in Drug Design & Discovery Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Current Cancer Drug Targets Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Epidemiology of Severe Sepsis Around the World
Endocrine, Metabolic & Immune Disorders - Drug Targets The Microarray Gene Profiling Analysis of Glioblastoma Cancer Cells Reveals Genes Affected by FAK Inhibitor Y15 and Combination of Y15 and Temozolomide
Anti-Cancer Agents in Medicinal Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
Current Cancer Drug Targets Future Targets for Immune Therapy in Colitis?
Endocrine, Metabolic & Immune Disorders - Drug Targets Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Effect of Dasatinib on Genes Related to Mitotic Catastrophe Pathway in Chronic Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry